Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
NRG Oncology
Mayo Clinic
University of Kentucky
Ohio State University Comprehensive Cancer Center
Fox Chase Cancer Center
Vanderbilt-Ingram Cancer Center
Emory University
Masonic Cancer Center, University of Minnesota
Ohio State University Comprehensive Cancer Center
University of California, Davis
University of California, San Francisco
Vanderbilt-Ingram Cancer Center